Sun Pharmaceutical announced the successful completion of its acquisition of Concert Pharmaceuticals for the development of deuruxolitinib, a novel, deuterated, oral JAK1/2 inhibitor, for the potential treatment of adult patients with moderate to severe alopecia areata.
This addition of deuruxolitinib, a late-stage, potential best-in-class treatment for alopecia areata, to the growing global dermatology portfolio expands the presence in the Boston biotech hub.
By bringing together Concert’s talented team with Sun Pharma’s global reach and commercial capabilities, this acquisition provides an opportunity to bring deuruxolitinib to market globally and make a meaningful difference to alopecia areata patients around the world.
Deuruxolitinib is an investigational oral selective inhibitor of Janus kinases JAK1 and JAK2. The U.S. Food and Drug Administration recently maintained Breakthrough Therapy designation for deuruxolitinib for the treatment of adult patients with moderate to severe alopecia areata and previously granted Fast Track designation for deuruxolitinib for the treatment of alopecia areata.